To CBD or Not to CBD? What Pharmacists Need to Know

To CBD or Not to CBD? What Pharmacists Need to Know is organized by American Pharmacists Association (APhA).,Initial release date: August 1, 2020,Expiration date: August 1, 2023,Activity Preview:,Today’s pharmacists face both a clinical and ethical dilemma surrounding the medical use of a DEA Schedule I drug marijuana, or specifically, one of its components, cannabidiol (CBD). CBD is a plant-derived compound from Cannabis sativa, the species of plant that includes both hemp and marijuana. In the United States, CBD is marketed in a range of consumer products—food and beverages, OTC supplements, personal care products, and cosmetics—that are subject to FDA regulation. Marketed consumer products containing plant-based CBD are either hemp-derived or marijuana-derived. This article summarizes the differences between the three types of cannabidiol (CBD) products. The author discusses the pharmacological properties, benefits, and risks of CBD, how to choose a high-quality hemp-derived CBD product and the dosing and adverse effects of CBD oil.,Learning Objectives:,At the completion of this knowledge-based activity, the participant will be able to:,• Summarize the differences between the three types of cannabidiol (CBD) products.,• List the dosing instructions and adverse effects of Epidiolex (cannabidiol oil).,• List the criteria for choosing a high-quality hemp-derived CBD product.,• Discuss the pharmacological properties of CBD.,• Identify the benefits and risks of CBD products.